Study
Study at UCL
Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.
Research
Research at UCL
Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).
Engage
Engage with UCL
Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.
About
About UCL
Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.

GS-US-292-1823

A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects

Project Summary

This study will evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in maintaining HIV-1 virologic suppression.

Key Project Information

Dates: September 2016 - May 2018 (completed)

UCL lead/Principal Investigator: Dr Laura Waters

Partners: Central and North West London NHS Foundation Trust

Location: Global

Funding: Gilead Sciences

Contact: mmc-research-cnwl@nhs.net

Dr Alejandro Arenas-Pinto

Marzia Fiorino

Dr Lewis Haddow

GS-US-292-1823

Project Summary

Key Project Information

Research Team